| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 81.41 | 7.7% | 25.1% |
| Total Income | 82.20 | 7.3% | 24.7% |
| Expenditure | 72.22 | 10.1% | 27.4% |
| PBT | 9.98 | 9.0% | 8.3% |
| Net Profit | 6.16 | 24.3% | 14.1% |
| OPM | 29.93% | 0.75pp | 0.45pp |
| NPM | 7.49% | 3.14pp | 3.39pp |
| EPS | 1.21 | 22.4% | 14.8% |
Suraksha Diagnostic FY26: Total Income Up 23% to ₹3,136 Million
21 May 2026 · 21 May, 9:12 pm
Summary
Suraksha Diagnostic Limited concluded FY26 with robust performance, reporting a total income of ₹3,135.78 million, marking a 22.5% year-on-year increase. EBITDA also grew by 15.8% to ₹985.58 million, achieving a 31.8% margin for the full year, while Profit After Tax rose by 1.4% to ₹314.04 million. Although Q4 FY26 saw strong top-line and EBITDA growth, profit after tax for the quarter declined by 14.1%. Joint Managing Director & CEO, Mrs. Ritu Mittal, highlighted sustained momentum from network expansion and improving market presence as key drivers, emphasizing ongoing investments for scale and long-term value creation through new centres and enhanced operational efficiencies.
Key Highlights
- 1
Suraksha Diagnostic Limited reported a 22.5% year-on-year increase in total income for the full financial year 2026, reaching ₹3,135.78 million.
- 2
EBITDA for FY26 grew by 15.8% to ₹985.58 million, translating to an EBITDA margin of 31.8%.
- 3
Profit After Tax (PAT) for the fiscal year 2026 saw a modest rise of 1.4% to ₹314.04 million, with an EPS of ₹6.2.
- 4
In the fourth quarter of FY26, total income surged by 24.7% year-on-year to ₹821.97 million, and EBITDA also increased significantly by 25.7% to ₹251.55 million.
- 5
Q4 FY26 Profit After Tax experienced a year-on-year decline of 14.1% to ₹61.59 million, resulting in a PAT margin of 7.6%.
- 6
The company demonstrated strong operational growth in FY26, with total tests increasing by 22.0% to 8.16 million and average revenue per patient growing by 7.1% to ₹2,264.
- 7
Suraksha Diagnostic significantly expanded its network during FY26 by adding 2 hubs, 11 spoke centres, and 4 Public-Private Partnership (PPP) facilities.
Management Comments
Mrs. Ritu Mittal
We concluded FY26 on a strong note, delivering healthy top-line growth driven by sustained momentum in our network expansion and improving market presence. The EBITDA margin continues to reflect investments towards newly launched centres and expansion initiatives. Our centres which are >2 years old continue to operate at a stable 36–37% EBITDA margin, demonstrating the resilience of our business model. We remain focused on ‘Investing for Scale: Short-term Compression for Long- term Value Creation.’ During FY26, we significantly expanded our footprint by adding 2 hubs, 11 spoke centres and 4 PPP, strengthening our reach and accessibility across key markets. Also, our recently launched genomic lab has picked up very well. Going forward, we remain committed to driving higher utilization across new centres, enhancing operational efficiencies, and delivering sustainable growth while creating long-term value for our shareholders.
Informational and educational content only. Not investment advice.